KCNN4 and neoplasm: We believe that these discrepancies regarding the proliferative and pharmacological properties of KCa3.1 in cancer cells should be resolved by proof-of-concept studies utilizing, for example, genetically engineered models allowing tumor cell- and tissue-specific knockout or expression of conditionally targeted KCa3.1 alleles in vivo.